Published in Vaccine on October 02, 2006
Safety and immunogenicity of tetanus-diphtheria-acellular pertussis vaccine administered to children 10 or 11 years of age. Clin Vaccine Immunol (2014) 0.75
Efficacy of fewer than three doses of an HPV-16/18 AS04-adjuvanted vaccine: combined analysis of data from the Costa Rica Vaccine and PATRICIA trials. Lancet Oncol (2015) 4.84
Importance of background rates of disease in assessment of vaccine safety during mass immunisation with pandemic H1N1 influenza vaccines. Lancet (2009) 4.07
Immunogenicity of 2 doses of HPV vaccine in younger adolescents vs 3 doses in young women: a randomized clinical trial. JAMA (2013) 3.06
Safety and immunogenicity of 26-valent group a streptococcus vaccine in healthy adult volunteers. Clin Infect Dis (2005) 3.06
Immunogenicity of a tetravalent meningococcal glycoconjugate vaccine in infants: a randomized controlled trial. JAMA (2008) 2.88
A portrait of the geographic dissemination of the Clostridium difficile North American pulsed-field type 1 strain and the epidemiology of C. difficile-associated disease in Québec. Clin Infect Dis (2006) 2.85
The changing age and seasonal profile of pertussis in Canada. J Infect Dis (2002) 2.53
Predictors of death in infants hospitalized with pertussis: a case-control study of 16 pertussis deaths in Canada. J Pediatr (2003) 2.42
Pandemic influenza in Canadian children: a summary of hospitalized pediatric cases. Vaccine (2010) 1.86
Risk of infection following a visit to the emergency department: a cohort study. CMAJ (2012) 1.83
Immunogenicity and safety of an inactivated quadrivalent influenza vaccine candidate: a phase III randomized controlled trial in children. J Infect Dis (2013) 1.70
Outbreak of atypical pertussis detected by polymerase chain reaction in immunized preschool-aged children. Pediatr Infect Dis J (2009) 1.67
Immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine administered as a 2-dose schedule compared with the licensed 3-dose schedule: results from a randomized study. Hum Vaccin (2011) 1.65
Burden of seasonal influenza in children with neurodevelopmental conditions. Pediatr Infect Dis J (2014) 1.63
Surveillance for influenza admissions among children hospitalized in Canadian immunization monitoring program active centers, 2003-2004. Pediatrics (2006) 1.59
Pediatric injuries from needles discarded in the community: epidemiology and risk of seroconversion. Pediatrics (2008) 1.51
Combined tetanus, diphtheria, and 5-component pertussis vaccine for use in adolescents and adults. JAMA (2005) 1.51
Inadequate pain management during routine childhood immunizations: the nerve of it. Clin Ther (2009) 1.51
Antibody responses in adult and neonatal BALB/c mice to immunization with novel Bordetella pertussis vaccine formulations. Vaccine (2011) 1.48
Cross-reactive and vaccine-induced antibody to an emerging swine-origin variant of influenza A virus subtype H3N2 (H3N2v). J Infect Dis (2012) 1.47
Prevention of CMV disease in pediatric kidney transplant recipients: evaluation of pp67 NASBA-based pre-emptive ganciclovir therapy combined with CMV hyperimmune globulin prophylaxis in high-risk patients. Pediatr Transplant (2008) 1.46
Epstein-Barr virus (EBV) early-antigen serologic testing in conjunction with peripheral blood EBV DNA load as a marker for risk of posttransplantation lymphoproliferative disease. J Infect Dis (2003) 1.45
Urinary tract infections in 1- to 3-month-old infants: ambulatory treatment with intravenous antibiotics. Pediatrics (2009) 1.44
Maternal Immunization With an Investigational Trivalent Group B Streptococcal Vaccine: A Randomized Controlled Trial. Obstet Gynecol (2016) 1.44
Is routine chest radiography necessary for the initial evaluation of fever in neutropenic children with cancer? Pediatr Blood Cancer (2004) 1.40
Dose-sparing H5N1 A/Indonesia/05/2005 pre-pandemic influenza vaccine in adults and elderly adults: a phase III, placebo-controlled, randomized study. J Infect Dis (2011) 1.40
The impact of childhood meningococcal serogroup C conjugate vaccine programs in Canada. Pediatr Infect Dis J (2009) 1.38
Polymorphisms of the fimbria fim3 gene of Bordetella pertussis strains isolated in Canada. J Clin Microbiol (2004) 1.34
Trivalent MDCK cell culture-derived influenza vaccine Optaflu (Novartis Vaccines). Expert Rev Vaccines (2009) 1.31
The effect of routine vaccination on invasive pneumococcal infections in Canadian children, Immunization Monitoring Program, Active 2000-2007. Vaccine (2009) 1.27
Outcome of penicillin-nonsusceptible Streptococcus pneumoniae meningitis: a nested case-control study. Pediatr Infect Dis J (2002) 1.26
Carotid artery dissection as a possible severe complication of pertussis in an adult: clinical case report and review. Clin Infect Dis (2002) 1.26
Risk factors for hospitalization and severe outcomes of 2009 pandemic H1N1 influenza in Quebec, Canada. Influenza Other Respir Viruses (2011) 1.24
A UMLS-based spell checker for natural language processing in vaccine safety. BMC Med Inform Decis Mak (2007) 1.24
Invasive Haemophilus influenzae type b infections in vaccinated and unvaccinated children in Canada, 2001-2003. CMAJ (2005) 1.24
Invasive infections caused by haemophilus influenzae serotypes in twelve Canadian IMPACT centers, 1996-2001. Pediatr Infect Dis J (2007) 1.23
Enhancing oral vaccine potency by targeting intestinal M cells. PLoS Pathog (2010) 1.22
The yin and yang of paracetamol and paediatric immunisations. Lancet (2009) 1.22
Three-year follow-up of protection rates in children given varicella vaccine. Can J Infect Dis (2002) 1.19
Immunization Monitoring Program, Active: a model of active surveillance of vaccine safety. Semin Pediatr Infect Dis (2003) 1.19
Single-day, patient-initiated famciclovir therapy for recurrent genital herpes: a randomized, double-blind, placebo-controlled trial. Clin Infect Dis (2005) 1.18
Comparison of children hospitalized with seasonal versus pandemic influenza A, 2004-2009. Pediatrics (2012) 1.13
Pertussis Across the Globe: Recent Epidemiologic Trends From 2000 to 2013. Pediatr Infect Dis J (2015) 1.12
Randomized controlled trial of dose response to influenza vaccine in children aged 6 to 23 months. Pediatrics (2011) 1.12
Antibody persistence and response to 2010-2011 trivalent influenza vaccine one year after a single dose of 2009 AS03-adjuvanted pandemic H1N1 vaccine in children. Vaccine (2011) 1.11
Safety and immunogenicity of two inactivated poliovirus vaccines in combination with an acellular pertussis vaccine and diphtheria and tetanus toxoids in seventeen- to nineteen-month-old infants. J Pediatr (1997) 1.10
Antibody persistence and the effect of a booster dose given 5, 10 or 15 years after vaccinating preadolescents with a recombinant hepatitis B vaccine. Vaccine (2012) 1.08
Costs and cost-effectiveness of a universal, school-based hepatitis B vaccination program. Am J Public Health (1998) 1.08
Response to the changing epidemiology of meningococcal disease in North America 1945-2010. Hum Vaccin Immunother (2013) 1.08
Pharmacological and Combined Interventions to Reduce Vaccine Injection Pain in Children and Adults: Systematic Review and Meta-Analysis. Clin J Pain (2015) 1.07
Epidemiological patterns and hospital characteristics associated with increased incidence of Clostridium difficile infection in Quebec, Canada, 1998-2006. Infect Control Hosp Epidemiol (2010) 1.07
Safety and immunogenicity of Haemophilus influenzae vaccine (tetanus toxoid conjugate) administered concurrently or combined with diphtheria and tetanus toxoids, pertussis vaccine and inactivated poliomyelitis vaccine to healthy infants at two, four and six months of age. Pediatr Infect Dis J (1994) 1.07
Distinct role of p38 and c-Jun N-terminal kinases in IL-10-dependent and IL-10-independent regulation of the costimulatory molecule B7.2 in lipopolysaccharide-stimulated human monocytic cells. J Immunol (2002) 1.05
An adult formulation of a five-component acellular pertussis vaccine combined with diphtheria and tetanus toxoids is safe and immunogenic in adolescents and adults. Vaccine (2000) 1.05
Mucosal immunization with a genetically engineered pertussis toxin S1 fragment-cholera toxin subunit B chimeric protein. Infect Immun (2003) 1.05
Characterization of liver histopathology in a transgenic mouse model expressing genotype 1a hepatitis C virus core and envelope proteins 1 and 2. J Gen Virol (2005) 1.04
Acellular vaccines for preventing whooping cough in children. Cochrane Database Syst Rev (2014) 1.04
The effect of funded varicella immunization programs on varicella-related hospitalizations in IMPACT centers, Canada, 2000-2008. Pediatr Infect Dis J (2012) 1.04
Human papillomavirus 16 (HPV 16) and HPV 18 antibody responses measured by pseudovirus neutralization and competitive Luminex assays in a two- versus three-dose HPV vaccine trial. Clin Vaccine Immunol (2011) 1.03
Azithromycin is as effective as and better tolerated than erythromycin estolate for the treatment of pertussis. Pediatrics (2004) 1.02
Substantial morbidity for hospitalized children with community-acquired rotavirus infections: 2005-2007 IMPACT surveillance in Canadian hospitals. Pediatr Infect Dis J (2010) 1.01
Health promotion and disease prevention in the emergency department: a feasibility study. CJEM (2006) 1.01
Bordetella holmesii bacteremia in asplenic children: report of four cases initially misidentified as Acinetobacter lwoffii. J Clin Microbiol (2010) 0.99
A dose-ranging study of a subunit Respiratory Syncytial Virus subtype A vaccine with and without aluminum phosphate adjuvantation in adults > or =65 years of age. Vaccine (2009) 0.98
The disease burden of invasive meningococcal serogroup B disease in Canada. Pediatr Infect Dis J (2013) 0.98
Heterogeneity of rotavirus testing and admitting practices for gastroenteritis among 12 tertiary care pediatric hospitals: Implications for surveillance. Can J Infect Dis Med Microbiol (2011) 0.98
The replicative activity of human endogenous retrovirus K102 (HERV-K102) with HIV viremia. AIDS (2007) 0.98
A novel vaccine adjuvant comprised of a synthetic innate defence regulator peptide and CpG oligonucleotide links innate and adaptive immunity. Vaccine (2009) 0.98
Role of D-alanylation of Streptococcus gordonii lipoteichoic acid in innate and adaptive immunity. Infect Immun (2007) 0.97
Safety and tolerability of a high-potency zoster vaccine in adults >/= 50 or years of age. Vaccine (2006) 0.97
Innovative bioinformatic approaches for developing peptide-based vaccines against hypervariable viruses. Immunol Cell Biol (2010) 0.96
Knowledge, attitudes, beliefs and behaviours of older adults about pneumococcal immunization, a Public Health Agency of Canada/Canadian Institutes of Health Research Influenza Research Network (PCIRN) investigation. BMC Public Health (2014) 0.96
Fatal group A Streptococcus purpura fulminans in a child receiving TNF-α blocker. Eur J Pediatr (2010) 0.96
Purification and immunogenicity of a recombinant Bordetella pertussis S1S3FHA fusion protein expressed by Streptococcus gordonii. Appl Environ Microbiol (2002) 0.95
[Why are some children incompletely vaccinated at the age of 2?]. Can J Public Health (2003) 0.95
Lack of evidence of encephalopathy related to pertussis vaccine: active surveillance by IMPACT, Canada, 1993-2002. Pediatr Infect Dis J (2004) 0.95
Expression of the Streptococcus mutans essential two-component regulatory system VicRK is pH and growth-phase dependent and controlled by the LiaFSR three-component regulatory system. Microbiology (2009) 0.94
The effect of changing from whole-cell to acellular pertussis vaccine on the epidemiology of hospitalized children with pertussis in Canada. Pediatr Infect Dis J (2007) 0.94
Differential regulation of CD44 expression by lipopolysaccharide (LPS) and TNF-alpha in human monocytic cells: distinct involvement of c-Jun N-terminal kinase in LPS-induced CD44 expression. J Immunol (2002) 0.94
Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine in healthy infants and toddlers given with routine pediatric vaccinations in Canada. Pediatr Infect Dis J (2012) 0.94
Epidemiological and economic burden of pneumococcal diseases in Canadian children. Can J Infect Dis (2003) 0.93
Canadian Association for Immunization Research and Evaluation (CAIRE) guidelines for industry-sponsored clinical trial and epidemiology contract research. Hum Vaccin (2005) 0.93
Profile of serogroup Y meningococcal infections in Canada: Implications for vaccine selection. Can J Infect Dis Med Microbiol (2009) 0.92
Susceptibility to measles, mumps, and rubella in newly arrived adult immigrants and refugees. Ann Intern Med (2007) 0.92
Systemic capillary leak syndrome presenting as recurrent shock. Pediatr Crit Care Med (2006) 0.92
Immunogenicity and immune memory of a nonadjuvanted quadrivalent meningococcal glycoconjugate vaccine in infants. Pediatr Infect Dis J (2009) 0.92
Assessment of causality of individual adverse events following immunization (AEFI): a WHO tool for global use. Vaccine (2013) 0.92
Immunization site pain: case definition and guidelines for collection, analysis, and presentation of immunization safety data. Vaccine (2012) 0.91
Novel vaccine formulations against pertussis offer earlier onset of immunity and provide protection in the presence of maternal antibodies. Vaccine (2013) 0.91
Clinical and microbiologic characteristics of group A streptococcal necrotizing fasciitis in children. Pediatr Infect Dis J (2009) 0.91